Manufacturing and use of human placenta-derived mesenchymal stromal cells for phase I clinical trials: Establishment and evaluation of a protocol

Nina Ilić; Kerry Atkinson

doi:10.2298/3730

Nina Ilić Mater Health Services, Brisbane, Queensland, Australia; Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Kerry Atkinson University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia; Queensland University of Technology, Brisbane, Queensland, Australia

DOI: https://doi.org/10.2298/3730

Keywords: stromal cells, therapeutics, clinical protocols, clinical medicine,

Abstract

Background/Aim. Mesenchymal stromal cells (MSCs) have been utilised in many clinical trials as an experimental treatment in numerous clinical settings. Bone marrow remains the traditional source tissue for MSCs but is relatively hard to access in large volumes. Alternatively, MSCs may be derived from other tissues including the placenta and adipose tissue. In an initial study no obvious differences in parameters such as cell surface phenotype, chemokine receptor display, mesodermal differentiation capacity or immunosuppressive ability, were detected when we compared human marrow derived-MSCs to human placenta-derived MSCs. The aim of this study was to establish and evaluate a protocol and related processes for preparation placenta-derived MSCs for early phase clinical trials. Methods. A full-term placenta was taken after delivery of the baby as a source of MSCs. Isolation, seeding, incubation, cryopreservation of human placenta-derived MSCs and used production release criteria were in accordance with the complex regulatory requirements applicable to Code of Good Manufacturing Practice manufacturing of ex vivo expanded cells. Results. We established and evaluated instructions for MSCs preparation protocol and gave an overview of the three clinical areas application. In the first trial, MSCs were co-transplanted iv to patient receiving an allogeneic cord blood transplant as therapy for treatment-refractory acute myeloid leukemia. In the second trial, MSCs were administered iv in the treatment of idiopathic pulmonary fibrosis and without serious adverse effects. In the third trial, MSCs were injected directly into the site of tendon damage using ultrasound guidance in the treatment of chronic refractory tendinopathy. Conclusion. Clinical trials using both allogeneic and autologous cells demonstrated MSCs to be safe. A described protocol for human placenta-derived MSCs is appropriate for use in a clinical setting, relatively inexpensive and can be relatively easily adjusted to a different set of regulatory requirements, as applicable to early phase clinical trials.

References

Locke M, Feisst V, Dunbar RP. Concise Review: Human Adi-pose-Derived Stem Cells: Separating Promise from Clinical Need. Stem Cells 2011; 29(3): 404−11.

Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, Rossetti T, et al. Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 2008; 17(6): 1095−107.

Berry MF, Engler AJ, Woo YJ, Pirolli TJ, Bish LT, Jayasankar V, et al. . Mesenchymal stem cell injection after myocardial infarc-tion improves myocardial compliance. Am J Physiol Heart Circ Physiol 2006; 290(6): 2196−203.

Brooke G, Tong H, Levesque JP, Atkinson K. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev 2008; 17(5): 929−40.

Brooke G, Rossetti T, Ilic N, Murray P, Hancock S, Atkinson K. Points to consider in designing mesenchymal stem cell-based clinical trials. Transf Med Hemother 2008; 35(4): 279−85.

Brooke G, Rossetti T, Pelekanos R, Ilic N, Murray P, Hancock S, et al. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Brit J Haem 2009; 144(4): 571−9.

Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001; 98(8): 2396−402.

Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mes-enchymal stem cells distribute to a wide range of tissues fol-lowing systemic infusion into nonhuman primates. Blood 2003; 101(8): 2999−3001.

Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al. Mitochondrial transfer from bone-marrow–derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012; 18(5): 759−65.

Caplan AI. Adult mesenchymal stem cells for tissue engineer-ing versus regenerative medicine. J Cell Physiol 2007; 213(2): 341−7.

Ilic N, Brooke G, Murray P, Barlow S, Rossetti T, Pelekanos R, et al. Manufacture of clinical grade human placenta-derived multi-potent mesenchymal stromal cells (MSC). In: Lucasgc VM, Rao MS, editors. Mesenchymal Stem Cell Assays and Applications. 1st ed. Heidelberg: Springer-Humana Press; 2011. p. 89−106.

Parolini O, Alviano F, Bagnara GP, Bilic G, Bühring H, Evangelista M, et al. Concise Review: Isolation and Characterization of Cells from Human Term Placenta: Outcome of the First In-ternational Workshop on Placenta Derived Stem Cells. Stem Cells 2008; 26(2): 300−11.

Ilic N, Khalil D, Hancock S, Atkinson K. Regulatory Considera-tions Applicable to Manufacturing of Placenta-Derived Mes-enchymal Stromal Cells (MSC) Used in Clinical Trials in Aus-tralia and Comparison to USA and European Regulatory Frameworks. In: Lucas CG, Vemuri MC, editors. Mesenchymal Stem Cell Therapy, Stem Cell Biology and Regenerative Medi-cine Series. 1st ed. Heidelberg: Springer-Humana Press. 2013. p. 373−404.

Heazlewood C, Cook M, Ilic N, Atkinson K. Exploring the Human Term Placenta as a Novel Source for Stem Cells and their Application in the Clinic. In: Zheng J, editor. Recent Advances in Research on the Human Placenta. 1st ed. Rijeka: In Tech; 2012. p. 53−76.

Ilic N, Savic S, Siegel E, Atkinson K, Tasic Lj. Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Austra-lia: part I--a method of manual documentary analysis. Stem Cells Transl Med 2012; 1(12): 898−908.

Ilic N, Savic S, Siegel E, Atkinson K, Tasic Lj. Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Austra-lia: part II--a method of software documentary analysis. Stem Cells Transl Med 2012; 1(12): 909−20.

Yen LB, Huang HI, Chien C, Jui H, Ko B, Yao M, et al. Isolation of multipotent cells from human term placenta. Stem Cells 2005; 23(1): 3−9.

Pendleton C, Li Q, Chesler D, Yuan K, Guerrero-Cazares H, Quinones-Hinojosa A. Mesenchymal Stem Cells Derived from Adipose Tissue vs. Bone Marrow: In vitro Comparison of Their Tropism towards Gliomas. PloS One 2013; 8(3): 58198.

Olson SD, Pollock K, Kambal A, Cary W, Mitchell G, Tempkin J, et al.. Genetically engineered mesenchymal stem cells as a pro-posed therapeutic for Huntington's disease. Mol Neurobiol 2012; 45(1): 87−98.

Burra P, Bizzaro D, Ciccocioppo R, Marra F, Piscaglia AC, Porretti L, et al. . Therapeutic application of stem cells in gastroen-terology: An up-date. World J Gastroenterol 2011; 17(34): 3870−80.

Yust-Katz S, Fisher-Shoval Y, Barhum Y, Ben-Zur T, Barzilay R, Lev N, et al. Placental mesenchymal stromal cells induced into neurotrophic factor-producing cells protect neuronal cells from hypoxia and oxidative stress. Cytotherapy 2012; 14(1): 45−55.

Yang YH, Lee AJ, Barabino GA. Coculture-Driven Mesenchy-mal Stem Cell-Differentiated Articular Chondrocyte-Like Cells Support Neocartilage Development. Stem Cells Transl Med 2012; 1(11): 843−54.

Shin L, Peterson DA. Human Mesenchymal Stem Cell Grafts Enhance Normal and Impaired Wound Healing by Recruiting Existing Endogenous Tissue Stem/Progenitor Cells. Stem Cells Transl Med 2013; 2(1): 33−42.

Deskins DL, Bastakoty D, Saraswati S, Shinar A, Holt GE, Young PP. Human Mesenchymal Stromal Cells: Identifying Assays to Predict Potency for Therapeutic Selection. Stem Cells Transl Med 2013; 2(2): 151−8.

Miranda-Sayago JM, Fernández-Arcas N, Benito C, Reyes-Engel A, Carrera J, Alonso A. Lifespan of human amniotic fluid-derived multipotent mesenchymal stromal cells. Cytotherapy 2011; 13(5): 572−81.

Gharibi B, Hughes FJ. Effects of Medium Supplements on Pro-liferation, Differentiation Potential, and In Vitro Expansion of Mesenchymal Stem Cells. Stem Cells Transl Med 2012; 1(11): 771−82.

Pieri L, Urbani S, Mazzanti B, Dal PS, Santosuosso M, Saccardi R, Vannucchi MG. Human mesenchymal stromal cells preserve their stem features better when cultured in the Dulbecco's modified Eagle medium. Cytotherapy 2011; 13(5): 539−48.

Nur FM, Chua K, Tan G, Tan A, Hayati A. Human chorion-derived stem cells: changes in stem cell properties during serial passage. Cytotherapy 2011; 13(5): 582−93.

Jones BJ, Brooke G, Atkinson K, McTaggart SJ. Immunosup-pression by placental indoleamine 2,3-dioxygenase: a role for mesenchymal stem cells. Placenta 2007; 28(11–12): 1174–81.